glp 1 vs sglt2 weight loss Inhibitors and the Clinical Implications of Associated in Type 2 Diabetes: A Narrative Review | Diabetes Therapy GLP‑1s & SGLT2s: Diabetes Weight

These direct immunomodulatory actions highlight a sophisticated interplay between the endocrine and immune systems

The FDA has approved the GLP-1 medication Wegovy for use in treating obesity and for some people who are overweight and have weight-related medical problems

Approval for Diabetes and Weight Management Over the past decade, three GLP-1/GIP receptor agonists liraglutide, semaglutide, and tirzepatide initially approved by the FDA for adults with type 2 diabetes, have also gained FDA approval for chronic weight management in people without diabetes, provided they meet specific criteria: a BMI of 30, or 27 with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes

Post-translational modifications required for coagulation factor secretion and function

If undiagnosed, diabetes can cause cardiovascular diseases, neuropathy (nerve damage), nephropathy (kidney damage), retinopathy (eye disorders), and even lower-limb amputation [1]